| 3.115 -2.255 (-41.99%) | 07-31 10:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.95 |
1-year : | 7.51 |
| Resists | First : | 5.09 |
Second : | 6.42 |
| Pivot price | 5.57 |
|||
| Supports | First : | 2.94 |
Second : | 2.44 |
| MAs | MA(5) : | 4.86 |
MA(20) : | 5.66 |
| MA(100) : | 4.81 |
MA(250) : | 5.82 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 10.1 |
D(3) : | 8.3  |
| RSI | RSI(14): 23 |
|||
| 52-week | High : | 8.59 | Low : | 2.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MYGN ] has closed below the lower bollinger band by 32.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MYGN ] is to continue within current trading range. It is unclear right now based on current values. 148.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.39 - 5.43 | 5.43 - 5.46 |
| Low: | 4.95 - 4.99 | 4.99 - 5.03 |
| Close: | 5.3 - 5.37 | 5.37 - 5.44 |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Fri, 31 Jul 2026
MYRIAD GENETICS INC 2026: Revenue $190.7M, EPS ($0.46) — 10-Q Summary - TradingView
Fri, 31 Jul 2026
[10-Q] MYRIAD GENETICS INC Quarterly Earnings Report - Stock Titan
Fri, 31 Jul 2026
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.86, Implies 9% Upside - TradingView
Fri, 31 Jul 2026
Myriad Genetics Inc (MYGN) (Q2 2026) Earnings Call Highlights: R - GuruFocus
Fri, 31 Jul 2026
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know - Benzinga
Thu, 30 Jul 2026
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 94 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 8,010 (K) |
| Shares Short P.Month | 8,650 (K) |
| EPS | -4.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.56 |
| Profit Margin | -41.3 % |
| Operating Margin | -21.5 % |
| Return on Assets (ttm) | -7.7 % |
| Return on Equity (ttm) | -23.6 % |
| Qtrly Rev. Growth | -20.8 % |
| Gross Profit (p.s.) | 4.01 |
| Sales Per Share | 5.89 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -0.73 |
| PEG Ratio | 1.2 |
| Price to Book value | 0.87 |
| Price to Sales | 0.53 |
| Price to Cash Flow | -11.31 |
| Dividend | 1.75 |
| Forward Dividend | 0 |
| Dividend Yield | 55.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|